NON-SMALL CELL LUNG CANCER

This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) and have no signs of cancer left. The goal is to see if the vaccine can train the immune system to recogniz…

This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and effective for people with advanced EGFR-mutant non-small cell lung cancer. About 48 participants will take both pills daily for up to 6 months. The goal is to see if the combination help…

This study tested giving immunotherapy drugs (nivolumab alone or with ipilimumab) before surgery to people with early-stage non-small cell lung cancer. The goal was to see if it is safe and can shrink tumors before removal. 39 participants received treatment, and researchers look…

This study looks at whether adding the targeted drug alectinib to standard chemotherapy is safe for people with a certain type of lung cancer (ALK-positive non-small cell lung cancer) after they have had surgery to remove the tumor. The trial involves 11 participants with stage I…

This study tested a new treatment plan for people with stage II or III non-small cell lung cancer. Participants first received precise radiation to the main tumor, then standard chemoradiation to the chest, followed by immunotherapy. The goal was to see if this combination could …

This early-stage study tests a high-dose radiation technique called SBRT for people with non-small cell lung cancer located in the very center of the chest (ultra-central). The main goal is to find the highest safe dose that keeps the risk of serious side effects under 30% within…

This study tests whether adding the drug durvalumab to precise radiation therapy (SBRT) can keep early-stage non-small cell lung cancer from coming back longer than radiation alone. It involves 13 adults with stage I to IIIA disease. The main goal is to see how long participants …

This study tests a combination of two immunotherapy drugs (zimberelimab and domvanalimab) as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The goal is to see if the combination can slow or stop cancer growth …

This study tests an oral drug called Mobocertinib in Japanese adults with non-small cell lung cancer. In the first part, different groups receive increasing doses to find the safest amount. In the second part, participants get that best dose to see if their tumors shrink. The goa…

This study tests a new pill (JDQ443) against standard chemotherapy (docetaxel) in people with advanced lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried chemotherapy and immunotherapy. The goal is to see if JDQ443 can delay canc…

This early-phase study tests whether combining two drugs, amivantamab and tepotinib, can help control non-small cell lung cancer with MET gene changes. The study involves about 3 adults with advanced cancer that cannot be removed by surgery. Researchers will monitor side effects …

This early-stage study tests the safety of a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or are hard to treat. The study involves 41 participants and will look at side effects and the right dose. It is not expected to …

This study tests whether a new combination of drugs (datopotamab deruxtecan plus rilvegostomig) or rilvegostomig alone can keep early-stage lung cancer from returning after surgery. It includes 24 people with stage I adenocarcinoma non-small cell lung cancer who have signs of can…

This study tests whether combining two drugs, pembrolizumab and vorinostat, can help people with advanced non-small cell lung cancer. About 120 adults with stage IV disease will receive either the combination or pembrolizumab alone. The goal is to see if the combo is safe and can…

This study tested whether adding tepotinib to osimertinib can help people with advanced non-small cell lung cancer whose cancer has a specific genetic change (MET amplification) and has stopped responding to osimertinib alone. About 140 participants received the combination thera…

This early-phase study tests a personalized cell therapy for people with certain advanced cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, sarcoma) that carry a protein called MAGE-A4. Patients' own immune cells are genetically modified to recognize and …

This study tests whether combining the drug durvalumab with radiation therapy can slow down cancer growth in people with locally advanced non-small cell lung cancer. About 61 adults with stage II or III lung cancer who would normally receive chemotherapy followed by radiation are…

This early-phase study tests a combination of two drugs, ceritinib and docetaxel, in people with advanced non-small cell lung cancer that does not have certain gene changes (ALK-negative, EGFR wild-type). The main goal is to find the safest dose and see if the combination can shr…

This study tests a daily pill called sunvozertinib given before surgery to people with a specific type of lung cancer (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors enough to make surgery more successful. 24 adults with stage II to IIIB non-small cell …

This study tests a new way to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one heart-related condition will be enrolled. Their primary care doctors will work more cl…

This study tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) whose disease has gotten worse after initial osimertinib treatment. About 98 participants w…

This study tests whether adding a new immunotherapy drug (relatlimab) to the usual nivolumab-plus-chemotherapy treatment can shrink tumors more effectively in people with advanced or recurrent non-small cell lung cancer. About 468 participants will receive either the three-drug c…

This study tests an experimental drug (ARRY-614) combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds the safest dose, and the second part checks i…

This study tests a drug called T-DXd (Enhertu) in 27 adults with advanced HER2-mutant lung cancer that has spread to the brain but is not causing symptoms. The main goal is to see how long the cancer in the brain stays under control. Participants receive the drug intravenously an…

This study tests a new approach for people with non-small cell lung cancer that has spread to a limited number of other body parts (up to 3 spots). Participants receive a combination of immunotherapy, chemotherapy, and precise radiation to the cancer spots, followed by surgery or…

This study tests whether adding radiation to a standard immunotherapy-plus-chemotherapy regimen can help people with advanced non-small cell lung cancer live longer. About 327 participants will receive either the triple combination or standard treatment. The goal is to improve ov…

This early-phase study tests an investigational drug called ABBV-400 in about 520 adults with advanced solid tumors, including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose, either alone or combined with another drug (bevacizumab). …

This early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…

This study tests a drug called sacituzumab govitecan combined with pembrolizumab (and sometimes chemotherapy) as a first treatment for people with advanced or metastatic non-small-cell lung cancer that doesn't have specific genetic changes. About 193 participants will receive the…

This study tests a new drug called SKB264 against standard chemotherapy in 376 adults with advanced non-squamous lung cancer that has a specific EGFR gene change and has stopped responding to targeted therapy. The goal is to see if SKB264 alone can help people live longer without…

This study was planned to test two drugs, Ezabenlimab and BI 907828, in people with advanced solid tumors like sarcoma, lung, breast, colorectal, or bile duct cancer. The goal was to see if the combination could control tumor growth for at least 24 weeks. However, the study was w…

This study looks at whether giving precise radiation to tumors that have just started to grow again can help people with metastatic breast or lung cancer live longer without their disease getting worse. About 107 adults with triple-negative breast cancer or certain types of lung …

This early-phase study tests the safety and effectiveness of combining two drugs, abemaciclib and pembrolizumab, in 100 people with advanced non-small cell lung cancer or a certain type of breast cancer (HR+/HER2-). The goal is to see if the combination can shrink tumors or slow …

This phase 3 trial compares two first-line treatments for advanced non-small-cell lung cancer with high PDL1 levels (50% or more). About 349 participants receive either pembrolizumab alone or pembrolizumab plus chemotherapy. The goal is to see if the combination delays cancer pro…

This study tests whether adding new drugs to the cancer treatment tislelizumab (with or without chemotherapy) can shrink tumors or slow cancer growth in people with advanced non-small cell lung cancer who haven't had treatment before. About 400 participants will join, split into …

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This early-phase study tests an experimental drug called KIN-2787 in about 400 adults with advanced solid tumors (including lung cancer and melanoma) that have specific BRAF or NRAS gene mutations. The main goals are to check safety, find the best dose, and see if the drug can sh…

This study tests whether sacituzumab govitecan, a targeted antibody carrying a chemotherapy drug, works better than the standard chemo docetaxel for people with advanced non-small cell lung cancer that has spread. About 600 participants whose cancer worsened after platinum chemo …

This early-stage study tests a new daily pill, zongertinib, in adults with advanced solid tumors (including lung cancer) that have HER2 gene changes and haven't responded to prior treatments. The first part finds the best dose; the second part checks if the drug shrinks tumors. P…

This study tests a highly targeted form of radiation therapy (SABR) in people with early-stage non-small cell lung cancer who also have interstitial lung disease, a condition that makes the lungs stiff and scarred. The goal is to see if this precise radiation can control the canc…

This early-stage study tests a new drug called amivantamab, alone or with other treatments, in people with advanced non-small cell lung cancer that has spread or cannot be removed. The goal is to find safe doses and see if the drug shrinks tumors. About 751 participants are invol…

This study tests an experimental drug, zelenectide pevedotin, in people with advanced non-small cell lung cancer that has a specific genetic change (NECTIN4 amplification) and has already been treated with at least one prior therapy. The goal is to see if the drug can shrink tumo…

This study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 1,410 participants will receive t…

This study tests whether adding immunotherapy to standard chemotherapy before surgery helps eliminate more tumor tissue in patients with advanced non-small cell lung cancer. About 90 participants will receive either chemo-immunotherapy or chemotherapy alone before surgery. The ma…

This study tests whether adding ramucirumab to the standard drug osimertinib can delay cancer growth in people with advanced EGFR-mutant non-small cell lung cancer. About 160 participants who have not had prior targeted therapy will be randomly assigned to receive either the comb…

This study tests a treatment for people with advanced lung cancer that has spread to the brain. It combines two immunotherapy drugs (nivolumab and ipilimumab) with a short course of chemotherapy. The goal is to see if this approach can control the brain tumors for at least 6 mont…

This study is for people with small cell or non-small cell lung cancer whose cancer has worsened after initial treatment. It tests a combination of three drugs: ADI-PEG 20, gemcitabine, and docetaxel. The first part finds the safest dose, and the second part checks how well the c…

This study tests a new drug called ivonescimab in people with non-small cell lung cancer who need surgery. The drug is given before surgery to shrink tumors and make them easier to remove. Researchers want to see if it works better than standard treatments and learn how it helps …

This study compares a new drug, DS-1062a, to the standard chemotherapy docetaxel in about 600 adults with advanced non-small cell lung cancer that has worsened after prior treatment. The main goals are to see if DS-1062a can delay cancer growth or improve survival. Participants r…

This study tests a combination of two or three experimental drugs (avutometinib, sotorasib, and defactinib) in people with a specific type of advanced lung cancer called KRAS G12C non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the …

This study tests a combination of three drugs—nivolumab, ipilimumab, and nintedanib—in people with advanced non-small cell lung cancer that cannot be cured. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18 or older and have …

This study tests a new drug called SI-B001 combined with chemotherapy in 69 people with advanced non-small cell lung cancer that no longer responds to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. Participants must have a specif…

This study tests several treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are chosen based on specific genetic markers (biomarkers) in their tumors. The goal is to see if these targeted therapies can delay cancer grow…

This study looks at people with advanced lung cancer whose cancer still shows a specific genetic change (EGFR mutation) after three weeks of the targeted drug osimertinib. Half of the 80 participants will keep taking osimertinib alone, while the other half will also get chemother…

This early-phase study tests a new drug called AB248, alone or with another drug (pembrolizumab), in adults with advanced solid tumors like lung cancer, melanoma, head and neck cancer, and kidney cancer. The main goals are to check safety and find the right dose. About 552 people…

This study tests an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors (e.g., ovarian, breast, prostate, lung cancer). The goal is to see if the drug is safe and can shrink tumors when given alone or with other anti-cancer medicines. About 70…

This study tests a combination of three drugs (zimberelimab, domvanalimab, and etrumadenant) in 30 adults with advanced non-small cell lung cancer who have already tried immunotherapy. The goal is to see if the triple therapy can shrink tumors or slow cancer growth. Researchers a…

This study tests whether adding chemotherapy to the targeted drug lazertinib can help people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) whose cancer stopped responding to lazertinib alone. About 87 adults will receive the combination and…

This study compares a new drug, BL-B01D1, to a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that no longer responds to immunotherapy or platinum chemo. About 698 adults with a specific type of lung cancer (EGFR wild-type) will take part. Th…

This early-phase study tests a new drug, BG-60366, designed to break down a faulty protein (mutant EGFR) that drives non-small cell lung cancer. About 33 adults with advanced or spreading lung cancer who have already tried other treatments will receive the drug to see if it is sa…

This study tests a combination of two drugs, alectinib and cobimetinib, for people with a specific type of advanced lung cancer called ALK-positive non-small cell lung cancer. The goal is to find the safest dose and see how well the drugs shrink tumors. About 16 adults will take …

This study tests a drug called taletrectinib in people with advanced lung cancer that has a specific genetic change (ROS1 positive). The goal is to see if the drug can shrink tumors and how safe it is. About 217 participants will receive the drug, and researchers will measure res…

This study tests whether the drug osimertinib, taken as a pill after surgery, can help prevent lung cancer from coming back in people with a specific rare gene change (uncommon EGFR mutation). About 51 adults with stage IB-IIIB non-small cell lung cancer will take the drug daily …

This trial tests a new antibody drug called acasunlimab (GEN1046) in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, to find safe doses, and second, to see how well the drug works alone or combined with other …

This study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer who haven't had treatment yet. Participants will receive either the targeted drug brigatinib alone or brigatinib plus chemotherapy. The goal is to see if the combination helps…

This study tests a new drug, BT5528, given alone or with another drug (nivolumab) in people with advanced solid tumors that have high levels of a protein called EphA2. The main goals are to find safe doses and learn about side effects. The study also checks if the drug can shrink…

This study tests a new drug called BL-B01D1, given alone or with another drug (osimertinib), in people with advanced non-small cell lung cancer that has spread. The goal is to see if the treatment shrinks tumors and is safe. About 198 adults with this type of lung cancer will tak…

This early-phase study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with pancreatic, lung, or co…

This study tests whether the immunotherapy drug atezolizumab can help prevent lung cancer from returning in people with stage IB to IIIA non-small cell lung cancer who have already had surgery and chemotherapy. About 1,280 participants will receive either atezolizumab for 16 cycl…

This study tests a new drug called tobemstomig combined with chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this combination works better than the current standard treatment (pembrolizumab plus chemo) at slo…

This study tests whether giving a higher dose of radiation to the most active parts of a lung tumor can lower the chance of cancer coming back in the chest. About 78 adults with advanced non-small cell lung cancer will get either standard chemoradiotherapy or chemoradiotherapy pl…

This phase 3 study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy before and after surgery helps people with stage II or IIIA non-small cell lung cancer. About 453 participants receive either tislelizumab plus chemo or a placebo plus chemo, foll…

This phase 3 study compares a new drug, SHR-A2009, with standard platinum-based chemotherapy in about 500 adults with advanced EGFR-mutated non-small cell lung cancer that has worsened after EGFR-targeted therapy. The main goal is to see if SHR-A2009 can delay cancer growth bette…

This study tests several targeted therapies for people with advanced or metastatic non-small cell lung cancer. A simple blood test identifies specific genetic changes in the cancer, allowing doctors to match patients with drugs that may shrink tumors or slow disease progression. …

This study tests a cancer-killing virus (VSV-IFNβ-NIS) given with an immunotherapy drug (pembrolizumab) in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine cancer, and kidney cancer. The goal is to find the safest and most effective virus do…

This study tests a combination of two targeted drugs, encorafenib and binimetinib, in people with a specific genetic mutation (BRAF V600E) in advanced non-small cell lung cancer. The goal is to see if the drugs can shrink tumors and slow the cancer's growth. About 119 adults with…

This study tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or chemoradiation can help people with stage IIB-IIIB non-small cell lung cancer. About 142 participants will receive the drug combination first, then either have sur…

This study tests a new oral drug, PLB1004, against standard chemotherapy (with or without an immunotherapy) in about 327 people with advanced non-small-cell lung cancer that has a specific genetic change called EGFR exon 20 insertion. The goal is to see if PLB1004 can keep the ca…

This study tests whether adding SKB264 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer without their disease getting worse. About 406 participants with PD-L1 positive tumors who have not had prior treatment will be ran…

This study tests whether combining two immunotherapy drugs, durvalumab and oleclumab, can help people with advanced lung cancer that hasn't spread after initial chemoradiation. About 30 adults with stage III non-small cell lung cancer will receive the drug combo. The main goal is…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease has progressed after standard immunotherapy. It tests a new drug combination designed to boost the immune system to fight cancer. About 40 participants will receive the experime…

This study tests whether adding the experimental drug uliledlimab to a standard immunotherapy (sintilimab) and chemotherapy can help people with advanced non-small cell lung cancer live longer without their cancer growing. About 150 adults who have not had prior treatment for the…

This study tests a combination of three treatments—an immune-boosting drug injected into a tumor (IL-2), targeted radiation, and the immunotherapy pembrolizumab—in adults with advanced lung, skin, kidney, or head-and-neck cancers that no longer respond to standard immunotherapy. …

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This study tests whether adding an immunotherapy drug (atezolizumab) to a standard chemotherapy (paclitaxel) and a targeted therapy (bevacizumab) can help people with advanced non-squamous lung cancer whose disease has worsened after prior immunotherapy and chemotherapy. About 15…

This phase 3 study tests a new drug called BL-B01D1 against standard chemotherapy in 432 adults with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to EGFR-targeted pills. The goal is to see if BL-B01D1 can delay cancer growth or …

This study tests a drug called DFMO combined with the immunotherapy pembrolizumab in people with advanced non-small cell lung cancer that has a specific gene change (STK11/LKB1). The goal is to find a safe dose and see if the combination shrinks tumors. About 45 adults will take …

This study tests a new drug called BL-M02D1 in people with advanced solid tumors, including non-small cell lung cancer that has not responded to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. About 14 adults will take part in this ea…

This study tested an oral drug called selpercatinib in 857 people with advanced solid tumors that have a specific RET gene change. The goal was to see if the drug is safe and can shrink tumors. While it may control the cancer, it is not a cure, and ongoing treatment is needed.

This phase 3 study tests whether a new drug called ensartinib works better than the current standard crizotinib for people with a specific type of advanced lung cancer (ALK-positive NSCLC). About 290 participants who have had up to one prior chemotherapy but no prior ALK inhibito…

This study tests whether a single, powerful dose of targeted radiation (SBRT) can be as safe and effective as multiple doses for people with central non-small cell lung cancer. About 30 participants with early-stage tumors will receive one treatment and be monitored for side effe…

This study tests a new combination of two drugs (tuvusertib and cemiplimab) in people with a type of advanced lung cancer that has stopped responding to standard treatments like immunotherapy and chemotherapy. The goal is to see if the combination can shrink tumors or slow the ca…

This early-phase study tests a new drug, HBI-2438, in people with advanced cancers (like lung, colon, or pancreatic) that have a specific genetic change called KRAS G12C. The main goal is to find the safest dose and check for side effects. About 44 adults who have tried other tre…

This study tests whether a daily pill called osimertinib can stop early-stage lung cancer from coming back after surgery. About 390 people with a specific gene mutation (EGFR) and stage IA2-IA3 non-small cell lung cancer will receive either osimertinib or a placebo for up to 3 ye…

This study tests two experimental drug combinations (durvalumab plus oleclumab or monalizumab) in adults with stage III lung cancer that cannot be removed by surgery. Participants have already completed chemotherapy and radiation and their cancer has not grown. The goal is to see…

This study is for people with advanced non-small cell lung cancer whose disease got worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations to see which ones might work better based on the specific features of each person's t…

This study tests whether adding thymosin alpha 1 to standard chemoradiation and immunotherapy helps people with advanced lung cancer complete a full year of immunotherapy. About 114 adults with non-small cell lung cancer that cannot be surgically removed will take part. The goal …

This study tests whether adding a special type of radiotherapy to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with stage III lung cancer that has spread to lymph nodes. About 90 participants will receive one of three radiation schedules …

This study tests an experimental drug called HFB200603, alone or with another immunotherapy (tislelizumab), in adults with advanced solid tumors like kidney, lung, skin, stomach, or colorectal cancer. The goal is to find a safe dose and see how well the body tolerates it. About 8…

This early-stage trial tests an experimental drug called RC148 in 121 people with advanced non-small cell lung cancer that cannot be removed by surgery. The drug is given alone or with other treatments to see if it can shrink tumors and control the disease. Participants must be i…

This study tests a new drug called SKB264, given alone or with other treatments, for people with advanced or spreading non-small cell lung cancer. About 356 adults with specific genetic types of lung cancer will take part. The goal is to see if the drug shrinks tumors and is safe…

This early-stage trial tests a new drug called BI-1910, alone or with pembrolizumab, in people with advanced solid tumors (like lung or liver cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug h…

This early-phase trial tests a treatment for adults with certain advanced solid tumors (like colorectal, lung, or breast cancer) that have spread and stopped responding to standard therapy. The approach uses a person's own white blood cells, which are genetically modified in a la…

This study compares a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) plus chemotherapy against the standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has not been treated before. About 1,021 pa…

This phase 3 study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) works better than osimertinib alone for people with advanced EGFR-mutant non-small cell lung cancer. About 587 participants are randomly assigned to receive either the combination or …

This study tests whether a new under-the-skin injection of the immunotherapy drug pembrolizumab works as well as the standard IV infusion for people with advanced non-small cell lung cancer. About 67 participants will receive either the shot or the IV, and researchers will measur…

This early-phase study tests a new drug, amivantamab, combined with standard targeted therapies (TKIs) in 12 adults with advanced non-small cell lung cancer that has specific gene changes (ALK, ROS1, or RET). The cancer has stopped responding to current treatments. The goal is to…

This study compares a new oral targeted therapy (DZD9008) to standard chemotherapy in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon20 insertion). About 324 participants who have not had prior treatment will be randomly assigned to r…

This program gives patients with serious non-small cell lung cancer access to the drug capmatinib when no other treatments are available and they cannot join a clinical trial. It is not a study to test the drug, but a way for doctors to request it for individual patients who migh…

This early-phase study tests whether combining two drugs—tepotinib and pembrolizumab—can help treat advanced non-small cell lung cancer (NSCLC) that doesn't respond to standard immunotherapy. The trial includes 19 adults with NSCLC, some with a specific MET gene mutation. The goa…

This study tests a two-step treatment approach for people with a certain type of lung cancer (EGFR-mutant, stages II to IIIB). First, patients take a targeted pill (almonertinib), then receive a combination of immunotherapy (adebrelimab) and chemotherapy. After these treatments, …

This early-stage study tests a new drug (RO7496353) combined with an immunotherapy drug, with or without chemotherapy, in people with advanced lung, stomach, pancreatic, or bladder cancers. The main goal is to check safety and how well the body tolerates the treatment. About 102 …

This study tests whether a drug called trilaciclib can prevent bone marrow suppression (low blood cell counts) caused by platinum chemotherapy in people with advanced non-small cell lung cancer. About 41 participants will receive trilaciclib before each chemo session. The main go…

This study tests a combination of two drugs, SI-B001 and osimertinib, in people with advanced non-small cell lung cancer that has stopped responding to previous treatments. The goal is to see if the combination can shrink tumors and control the disease. About 14 adults with speci…

This study tests a new drug called divarasib against two existing drugs (sotorasib and adagrasib) for people with a specific type of advanced lung cancer (KRAS G12C-positive non-small cell lung cancer). About 338 participants who have already tried other treatments will be random…

This study tests an experimental drug called AB-106 in 173 adults with advanced non-small cell lung cancer that has a specific genetic change (ROS1 fusion). The goal is to see if the drug can shrink tumors and to check for side effects. Participants must have tried other targeted…

This study looks at whether adding stereotactic radiotherapy (precise radiation) can help control brain metastases that remain after initial drug therapy in people with non-small cell lung cancer. About 202 participants will be randomly assigned to receive either standard drug tr…

This study looks at whether adding a special type of radiation (SABR) to usual cancer therapy can help people with non-small cell lung cancer that has spread to only a few places in the body. About 140 adults will be randomly assigned to get either standard treatment alone or sta…

This study looks at whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy can help people with non-small cell lung cancer. About 43 participants will receive the vitamin C alongside their standard therapy. The goal is to see if this c…

This study tests a combination of two drugs, nivolumab and ramucirumab, in people with advanced non-small cell lung cancer that has come back or spread. Participants have already received immunotherapy. The main goal is to see if the combination can control the disease by shrinki…

This study tests whether giving the drug cemiplimab (alone or with fianlimab) before surgery can shrink tumors in people with lung, liver, or head/neck cancers. About 65 participants will receive the drug and then have surgery to remove their cancer. Researchers will check how mu…

This study tests an experimental drug, telisotuzumab vedotin, in about 270 adults with a certain type of advanced lung cancer (c-Met+ non-small cell lung cancer) that has already been treated. The drug works like a guided missile, delivering chemotherapy directly to cancer cells …

This study tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking these faulty genes. About 534 adults with various cancers, including lung, breast, and br…

This study tests the safety of adding an experimental drug (MPDL3280A) to standard chemotherapy and radiation for people with a type of lung cancer that cannot be removed by surgery. About 52 participants will receive the combination therapy. The main goal is to see how safe the …

This study tests a new drug called DS-1062a in people with advanced solid tumors, including certain lung and breast cancers that have not responded to standard treatments. It is the first time this drug is being used in humans, and the main goals are to check its safety and find …

This study tests a new drug called DZD9008 (sunvozertinib) in people with advanced non-small cell lung cancer that has specific gene changes (EGFR or HER2 mutations) and has stopped responding to other treatments. The goal is to check the drug's safety, side effects, and how well…

This study tests a new drug called GDC-6036 in people with advanced cancers (like lung or colon cancer) that have a specific gene change called KRAS G12C. The goal is to find safe doses and see if the drug works alone or with other treatments. About 500 adults will take part in t…

This early-phase study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The therapy uses donor immune cells engineered to attack cance…

This study tests a combination of three drugs (amivantamab, lazertinib, and bevacizumab) in 60 people with advanced EGFR-mutant non-small cell lung cancer whose disease worsened after previous treatment. The goal is to see if adding two drugs to a standard targeted therapy can sh…

This study tests whether adding the drug durvalumab to standard chemotherapy and radiation helps people with stage III lung cancer that cannot be removed by surgery. About 328 participants received either durvalumab or a placebo alongside their usual treatment. The main goal is t…

This study tests whether adding a drug called savolitinib to the standard treatment osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR mutation-positive and MET amplified). About 30 adults whose cancer got worse on osi…

This study tests whether adding a new drug (uliledlimab) to an immunotherapy (toripalimab) works better than either toripalimab or pembrolizumab alone for people with advanced non-small cell lung cancer that has certain markers (PD-L1 and CD73). About 450 adults who have not had …

This study tests the drug atezolizumab in 60 people with advanced non-small cell lung cancer whose tumors have high levels of a protein called PD-L1 and who have not had chemotherapy before. The goal is to see if the drug helps them live longer and slows cancer growth. Participan…

This early-phase study tests two experimental immunotherapy drugs (botensilimab and balstilimab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 499 participants with various can…

This early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…

This study tests an experimental pill called BDTX-1535 for people with advanced non-small cell lung cancer or a type of brain tumor called glioblastoma that have certain genetic changes. The goal is to find the best dose and see if the drug can shrink tumors or slow their growth.…

This study tests whether combining two targeted drugs, osimertinib and selumetinib, can shrink tumors and delay cancer growth in people with advanced EGFR-mutant non-small cell lung cancer who have not taken EGFR inhibitors before. About 25 participants will receive the drug comb…

This study offers continued treatment with lorlatinib for people with ALK-positive or ROS1-positive non-small cell lung cancer who are already benefiting from it in earlier Pfizer studies. The main goal is to monitor long-term safety and side effects. About 76 participants will t…

This study tests a new drug called selpercatinib against standard chemotherapy for people with a specific type of advanced lung cancer (RET fusion-positive non-small cell lung cancer). About 261 participants will be randomly assigned to receive either selpercatinib or standard tr…

This study tests a combination of two drugs, ensartinib and bevacizumab, in people with advanced lung cancer that has specific genetic changes (ALK rearrangement and TP53 mutation). The goal is to see if the combo can keep the cancer from growing for at least 12 months. About 47 …

This study tests a new drug called JDQ443, given alone or with other treatments, for people with advanced solid tumors that have a specific change in the KRAS gene (G12C). The goal is to find safe doses and see if the drug can shrink tumors. About 74 adults with lung or colorecta…

This early-phase study tests an experimental drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose,…

This study looks at how safe and effective XALKORI is for people with a specific kind of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not taken this drug before. Researchers will track side effects and measure how well the drug shrinks tumors. About 97…

This study tested a drug called abemaciclib against another drug, erlotinib, in people with advanced lung cancer that has a specific gene change (KRAS mutation) and has stopped responding to chemotherapy. The goal was to see if abemaciclib helps people live longer. About 450 adul…

This study tests an experimental drug called PF-06801591 that helps the immune system fight cancer. It is for people with advanced solid tumors or non-small-cell lung cancer that has not responded to other treatments. The goal is to see if the drug is safe and can control the can…

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors, including bladder, breast, lung, and other cancers. The goal is to find a safe and effective dose and see if the drug can shrink tumors. About 490 participants will take p…

This study tests an experimental drug called HFB200301, alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The main goal is to find safe doses and check for side effects. About 72 people will take part, and the st…

This study tests whether adding an experimental drug (fianlimab) to standard immunotherapy (cemiplimab) and chemotherapy works better than the standard combination alone for people with advanced non-small cell lung cancer. About 950 participants who have not had prior treatment f…

This study tests whether adding a cholesterol-lowering drug (alirocumab) to standard chemotherapy and immunotherapy (cemiplimab) before surgery can improve outcomes for people with early-stage non-small cell lung cancer (stages 1B-3A). About 126 participants will receive either t…

This study tested whether adding hydroxychloroquine (a malaria drug) to the standard targeted therapy erlotinib could help delay resistance in people with advanced non-small cell lung cancer that has specific EGFR mutations. The trial enrolled 76 participants and measured how lon…

This early-phase study tests an experimental oral drug, HBI-2376, in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific KRAS or EGFR gene mutations. The main goal is to find the safest dose and check for side effects. About 42 participan…

This study compares two standard treatments for stage I non-small cell lung cancer: surgery and a precise type of radiation called stereotactic body radiation therapy (SBRT). About 446 patients will be followed for up to 3 years to see which treatment leads to better survival and…

This study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese adults with a specific genetic mutation (BRAF V600E) in advanced non-small cell lung cancer that has spread. Participants must not have received prior treatment with similar drugs. The g…

This early-stage trial tests a new drug, MK-2870, alone or with pembrolizumab (with or without chemotherapy) in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check safety and find the right dose. About 30 participants will be enrolled.

This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will r…

This study is testing whether a simple blood test, called a liquid biopsy, can help doctors decide on treatment for advanced lung cancer faster than the current standard method, which requires testing a piece of the tumor. Researchers will compare how long it takes to get results…

This study looks at whether adding acupuncture to standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer. About 60 participants will receive either real or sham acupuncture alongside their first four cycles of treatment. The goal is to se…

This study looks at whether people with certain cancers prefer getting the drug pembrolizumab as a shot under the skin instead of through an IV. About 147 participants will try both methods and report which they like better. The goal is to see if the shot is a more convenient opt…

This study tests a supportive care program for adults who have finished treatment for lung cancer or mesothelioma. The goal is to help improve quality of life during the transition to regular check-ups. About 21 participants will try the program, and researchers will see if it is…

This study looks at two ways to give radiation to people with cancer that has spread to the brain. All participants are also receiving immunotherapy. The standard approach gives a single high dose of radiation, while the experimental approach gives a lower dose over a few days. T…

This study follows over 2,700 patients with bladder, lung, or liver cancer who received the drug atezolizumab as part of their normal care. Researchers are tracking how long patients live and how well the drug controls the cancer outside of strict clinical trial settings. The goa…

This study collects tumor samples from over 3,000 adults with advanced cancers to look for specific genetic markers, called biomarkers. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants do not receive a new tre…

This study looks at the bacteria living in the lungs, airways, and gut of 40 people with non-small cell lung cancer. Half receive surgery only, the other half also get chemotherapy. Researchers want to see how these bacteria differ and change, which could help design future studi…

This study examines 100 people with a certain type of advanced lung cancer (EGFR-mutated NSCLC) to see how often they have a DNA repair problem called HRD. Researchers will look at tumor samples and medical records to find links between HRD and how the cancer behaves. The goal is…

This study compares two types of minimally invasive lung surgery for people with early-stage lung cancer: robotic surgery and video-assisted surgery. The goal is to see if one leads to better quality of life or lower costs. About 446 adults will take part, and the results will he…

This study tests whether a team of specialists (Molecular Tumor Board) can help people with advanced lung cancer live longer and feel better compared to usual care. About 659 adults with stage IIb to IV non-small cell lung cancer who haven't had treatment yet will take part. The …

This study reviews how patients with non-small-cell lung cancer that has spread only to a few spots in the brain were treated. The goal is to find which treatment strategy works best. Researchers will look at medical records of 46 adults treated at two hospitals in France.

This study looks at the best way to collect tissue samples from people with suspected lung cancer during a routine ultrasound procedure. It compares taking 2 versus 3 samples from each lymph node to see which method provides enough material for genetic testing. The study also che…

This early trial tests whether using real-time MRI to guide radiation therapy is practical for people with advanced lung cancer. The goal is to see if this personalized approach can reduce side effects and better control tumors. About 30 participants will receive the treatment to…

This study collects white blood cells and tumor cells from up to 7,000 cancer patients and healthy volunteers. The cells are used in the lab to grow large numbers of immune cells that may be given back to patients in future experimental treatments. No direct treatment is provided…

This study looks at how tiny differences in your DNA (called SNPs) might influence how well the drug alectinib works against non-small cell lung cancer, and whether it causes side effects. Researchers will analyze blood samples from 600 patients to find genetic markers linked to …

This study observes 274 adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). It looks at how doctors use the drug osimertinib as the first treatment and how patients do over 36 months, including survival and quality of life. The goal…

This study aims to collect medical history and tissue or saliva samples from 100 people with advanced ALK+ non-small cell lung cancer. Researchers will use these samples to study the immune system and genetic markers of the disease. The goal is to better understand ALK+ lung canc…

This study looks at whether a simple blood test that detects tumor DNA can help doctors decide when it's safe for people with advanced melanoma or lung cancer to stop immunotherapy. About 39 patients who have been on treatment for at least a year and show no tumor DNA in their bl…

This study looks at how PET/CT scans can be used with artificial intelligence to better understand non-small cell lung cancer. Researchers will analyze scans from 500 patients to see if they can predict cancer stage, type, gene changes, and patient outcomes. The goal is to help d…

This study looks at how the heart works during standard treatment for advanced lung cancer. Researchers measured heart function in 231 patients while they walked for six minutes. The goal was to see if heart changes could help predict side effects and survival. This is an observa…

This study looks at how doctors in Russia treat advanced lung cancer (NSCLC) in everyday practice. Researchers will follow about 1500 adults to see which treatments are used and how genetic testing guides decisions. The goal is to understand real-world care, not to test a new dru…

This study is looking at whether changes in a blood test called tumor fraction can help predict how well immunotherapy works in people with non-small cell lung cancer or kidney cancer. About 100 adults are taking part, and researchers will also look at inflammation, hormone level…

This phase 2 trial is testing the drug durvalumab in 25 people with operable non-small cell lung cancer to see how it changes the immune system before their tumor is removed. The main goal is to measure how many tumors shrink or have fewer than 10% viable cancer cells after treat…

This study looks at whether PET-CT scans can accurately predict if non-small cell lung cancer has spread to nearby lymph nodes. Researchers will compare scan results with actual tissue samples from surgery in 280 patients. If successful, this could help doctors decide on treatmen…

This study looks at past medical records and brain scans from 380 adults with non-small cell lung cancer that has spread to the brain. Researchers are testing whether a computer model can predict certain genetic changes (EGFR or ALK) from routine MRI images, which could help guid…

This study looks at how doctors use the VeriStrat blood test to decide treatments for non-small cell lung cancer. About 5,000 patients are involved. The goal is to see if the test improves treatment choices and to explore new tests that might predict which medicines work best for…

This study looks at a new technique called OSNA that can quickly detect tiny amounts of cancer in lymph nodes from lung cancer surgery. About 130 people with early-stage lung cancer will have their lymph nodes checked either with OSNA or the usual lab methods. The goal is to see …

This study screens up to 1,150 adults with advanced solid tumors (like head and neck, cervical, or lung cancer) to check their genetic markers and tumor features. The goal is to find who might qualify for future experimental T-cell therapies that target specific cancer antigens. …